Calidad de sueño en los atletas de los XXII Juegos Centroamericanos y del Caribe, Veracruz 2014

Resumen Introducción: Con el objeto de evaluar la calidad del sueño en los atletas de los Juegos Centroamericanos y del Caribe, Veracruz 2014, se realizó el presente estudio durante el periodo de la competencia. Materiales y métodos: El estudio se realizó en una muestra no probabilística con un diseño transversal. Para la evaluación del sueño se utilizó el cuestionario: Índice de calidad del sueño de Pittsburgh. El estudio fue previamente revisado y aprobado por el Comité de Ética del Centro de Medicina de la Actividad Física y el Deporte (cemafyd). Resultados: Se realizaron 312 encuestas en atletas que participaron en los xxii Juegos Centroamericanos y del Caribe, la edad promedio fue de 24.0 ± 5.3 años para las mujeres y de 25.4 ± 6.3 años para los hombres (p=0.11). Se obtuvo una mayor frecuencia para una buena calidad de sueño (n=176) vs una mala calidad de sueño (n=136) con una diferencia estadística significativa entre ambas frecuencias (p=0.02). No hay asociación entre la calidad de sueño y el género de los atletas, sin embargo, al parecer existe una relación entre el tipo de deporte individual o de conjunto y la calidad del sueño (p=0.01). Conclusiones: El 44% de los atletas presentó mala calidad de sueño, dato de preocupación para una población con actividad física constante. Abstract Introduction: In order to evaluate the quality of sleep in the athletes of Central American Games and of the Caribbean, Veracruz 2014 the present study was conducted during the competition. Material and methods: The study was conducted in a sample not probabilistic with a cross-sectional design. The questionnaire was used for the evaluation of sleep: the Pittsburgh sleep quality index. The study was previously reviewed and approved by the Ethics Committee of the center of Medicine of physical activity and Sport (CEMAFyD). Results: 312 surveys were conducted in athletes who took part in the 22ND Central American Games and of the Caribbean, the average age was 24.0 ± 5.3 years for women and 25.4 ± 6.3 years for males (p = 0.11). A higher frequency for a good quality of sleep obtained (n = 176) versus a bad quality of sleep (n = 136) with a significant statistical difference between both frequencies (p = 0.02). There is no association between the quality of sleep and the genre of the athletes, but apparently there is a relationship between individual sport or set type and the quality of sleep (p = 0.01). Conclusions: 44% of the athletes presented poor quality of sleep, information of concern for a population with constant physical activity

Calidad de sueño en los atletas de los XXII Juegos Centroamericanos y del Caribe, Veracruz 2014

Resumen Introducción: Con el objeto de evaluar la calidad del sueño en los atletas de los Juegos Centroamericanos y del Caribe, Veracruz 2014, se realizó el presente estudio durante el periodo de la competencia. Materiales y métodos: El estudio se realizó en una muestra no probabilística con un diseño transversal. Para la evaluación del sueño se utilizó el cuestionario: Índice de calidad del sueño de Pittsburgh. El estudio fue previamente revisado y aprobado por el Comité de Ética del Centro de Medicina de la Actividad Física y el Deporte (cemafyd). Resultados: Se realizaron 312 encuestas en atletas que participaron en los xxii Juegos Centroamericanos y del Caribe, la edad promedio fue de 24.0 ± 5.3 años para las mujeres y de 25.4 ± 6.3 años para los hombres (p=0.11). Se obtuvo una mayor frecuencia para una buena calidad de sueño (n=176) vs una mala calidad de sueño (n=136) con una diferencia estadística significativa entre ambas frecuencias (p=0.02). No hay asociación entre la calidad de sueño y el género de los atletas, sin embargo, al parecer existe una relación entre el tipo de deporte individual o de conjunto y la calidad del sueño (p=0.01). Conclusiones: El 44% de los atletas presentó mala calidad de sueño, dato de preocupación para una población con actividad física constante. Abstract Introduction: In order to evaluate the quality of sleep in the athletes of Central American Games and of the Caribbean, Veracruz 2014 the present study was conducted during the competition. Material and methods: The study was conducted in a sample not probabilistic with a cross-sectional design. The questionnaire was used for the evaluation of sleep: the Pittsburgh sleep quality index. The study was previously reviewed and approved by the Ethics Committee of the center of Medicine of physical activity and Sport (CEMAFyD). Results: 312 surveys were conducted in athletes who took part in the 22ND Central American Games and of the Caribbean, the average age was 24.0 ± 5.3 years for women and 25.4 ± 6.3 years for males (p = 0.11). A higher frequency for a good quality of sleep obtained (n = 176) versus a bad quality of sleep (n = 136) with a significant statistical difference between both frequencies (p = 0.02). There is no association between the quality of sleep and the genre of the athletes, but apparently there is a relationship between individual sport or set type and the quality of sleep (p = 0.01). Conclusions: 44% of the athletes presented poor quality of sleep, information of concern for a population with constant physical activity

Fertilidad y producción de caña de azúcar en Hueyapan De Ocampo, Veracruz, México

Se analizaron las principales características químicas para determinar el estado de fertilidad de los suelos tipo Andosol, Vertisol y Gleysol, donde se establece el sistema productivo caña de azúcar en Zapoapan de Amapan perteneciente al municipio de Hueyapan de Ocampo del estado de Veracruz. La importancia de este trabajo radica en ubicar la situación que origina rendimientos muy por debajo de lo que se específica para México. El objetivo del presente trabajo fue evaluar los parámetros pH, materia orgánica, conductividad eléctrica, nitrógeno inorgánico, fósforo, contenidos de potasio, calcio, magnesio, fierro, cobre, manganeso, boro y densidad aparente, siguiendo los métodos establecidos en la NOM-021-RECNAT-2000, para ubicar el estado de fertilidad de los suelos y los posibles impactos ambientales ejercidos sobre este recurso natural. Los resultados mostraron que los suelos andosoles tuvieron las mejores condiciones de fertilidad para el cultivo de caña de azúcar; en tanto que los suelos tipo vertisol mostraron problemas leves de contaminación por los contenidos de boro obtenidos. La materia orgánica y el nitrógeno inorgánico son las variables que se deben atender para mejorar la fertilidad de los suelos. La producción de caña de azúcar en la comunidad de Zapoapan de Amapan, es baja (de 25 a 50 ton hectárea), por lo que se recomienda mejorar las prácticas agrícolas con el fin de incrementar los contenidos de nutrimentos en los tres tipos de suelo

Monitoreo de la frecuencia cardiaca como indicador de la intensidad del entrenamiento en el futbolista profesional a 2 600 m sobre el nivel del mar

Resumen Introducción: Con el objetivo de analizar el comportamiento de la frecuencia cardiaca como indicador de la intensidad del entrenamiento en el futbolista profesional a 2 600 m sobre el nivel del mar. Materiales y métodos: Se realizó un estudio longitudinal, prospectivo de la temporada apertura 2017 y clausura 2018 del fútbol mexicano, con un análisis estadístico descriptivo con medidas de tendencia central y de dispersión, así como intervalos de confianza en un análisis de 2 328 monitoreos de la frecuencia cardiaca y distancia recorrida con el sistema de seguimiento por GPS Polar Team Pro y 111 monitoreos ambientales, con una duración aproximada de 120 minutos por sesión de entrenamiento. Resultados: Se llevaron a cabo 2 328 monitoreos con registros de frecuencia cardiaca en reposo, variabilidad de la frecuencia cardiaca (vfc), frecuencia cardiaca durante el entrenamiento y la recuperación; con 111 registros ambientales. Algunas de las variables propias del monitoreo de la frecuencia cardiaca durante el entrenamiento por la dinámica del mismo, como lo es, no seguir indicaciones o impuntualidad por el deportista; así como los tiempos propios marcados por el entrenador, falla del registro por desconexión del sensor, entre otras, hacen que algunos registros no sean valorables. Conclusiones: La frecuencia cardiaca de reposo permanece en los parámetros normales, la frecuencia cardiaca media de entrenamiento se encuentra en zona 2 de control de peso entre el 60-70% de la frecuencia cardiaca máxima, y la frecuencia cardiaca máxima de esfuerzo dentro de la zona 5 de alta intensidad, mientras que la frecuencia cardiaca mínima se ubica por debajo de la zona 1 de actividad regenerativa que va de un 50-60% de la frecuencia cardiaca máxima. Abstract Introduction: The purpose of this study is to analyze the behavior of the cardiac variability as an indicator of the training intensity in football players at 2600mts altitude above sea level. Methods: This was a longitudinal and prospective study of the 2017-2018 Mexican football seasons, with a descriptive analysis and central tendency on dispersion measurements as confidence intervals. These intervals consisted of 2328 heart rate cardiac monitorizations,traveled distance with the Polar Team Pro GPS tracking system and 111 environmental monitorizations, with each training session length of 120 minutes approximately. Results: After making 2328 monitorizations the following measures were obtained: resting heart rate, heart rate variability (hrv), heart rate during training and recovery sessions amongst 111 environmental registrations. Some variables of the heart rate monitorization records during the training session couldn´t be measured or valued such as not following instructions, football players running late, the coach training marked times, and the cardiac monitor connection errors. Conclusions: The resting heart rate is between the normal parameters. The medium heart rate is between 60-70% of the maximum heart rate of the second zone of weight control. The maximum heart rate posterior to the effort is in the fifth zone of high intensity, meanwhile the minimum heart rate is below the first zone of regenerative activity that corresponds from 50-60% of the maximum heart rate

Monitoreo de la frecuencia cardiaca como indicador de la intensidad del entrenamiento en el futbolista profesional a 2 600 m sobre el nivel del mar

Resumen Introducción: Con el objetivo de analizar el comportamiento de la frecuencia cardiaca como indicador de la intensidad del entrenamiento en el futbolista profesional a 2 600 m sobre el nivel del mar. Materiales y métodos: Se realizó un estudio longitudinal, prospectivo de la temporada apertura 2017 y clausura 2018 del fútbol mexicano, con un análisis estadístico descriptivo con medidas de tendencia central y de dispersión, así como intervalos de confianza en un análisis de 2 328 monitoreos de la frecuencia cardiaca y distancia recorrida con el sistema de seguimiento por GPS Polar Team Pro y 111 monitoreos ambientales, con una duración aproximada de 120 minutos por sesión de entrenamiento. Resultados: Se llevaron a cabo 2 328 monitoreos con registros de frecuencia cardiaca en reposo, variabilidad de la frecuencia cardiaca (vfc), frecuencia cardiaca durante el entrenamiento y la recuperación; con 111 registros ambientales. Algunas de las variables propias del monitoreo de la frecuencia cardiaca durante el entrenamiento por la dinámica del mismo, como lo es, no seguir indicaciones o impuntualidad por el deportista; así como los tiempos propios marcados por el entrenador, falla del registro por desconexión del sensor, entre otras, hacen que algunos registros no sean valorables. Conclusiones: La frecuencia cardiaca de reposo permanece en los parámetros normales, la frecuencia cardiaca media de entrenamiento se encuentra en zona 2 de control de peso entre el 60-70% de la frecuencia cardiaca máxima, y la frecuencia cardiaca máxima de esfuerzo dentro de la zona 5 de alta intensidad, mientras que la frecuencia cardiaca mínima se ubica por debajo de la zona 1 de actividad regenerativa que va de un 50-60% de la frecuencia cardiaca máxima. Abstract Introduction: The purpose of this study is to analyze the behavior of the cardiac variability as an indicator of the training intensity in football players at 2600mts altitude above sea level. Methods: This was a longitudinal and prospective study of the 2017-2018 Mexican football seasons, with a descriptive analysis and central tendency on dispersion measurements as confidence intervals. These intervals consisted of 2328 heart rate cardiac monitorizations,traveled distance with the Polar Team Pro GPS tracking system and 111 environmental monitorizations, with each training session length of 120 minutes approximately. Results: After making 2328 monitorizations the following measures were obtained: resting heart rate, heart rate variability (hrv), heart rate during training and recovery sessions amongst 111 environmental registrations. Some variables of the heart rate monitorization records during the training session couldn´t be measured or valued such as not following instructions, football players running late, the coach training marked times, and the cardiac monitor connection errors. Conclusions: The resting heart rate is between the normal parameters. The medium heart rate is between 60-70% of the maximum heart rate of the second zone of weight control. The maximum heart rate posterior to the effort is in the fifth zone of high intensity, meanwhile the minimum heart rate is below the first zone of regenerative activity that corresponds from 50-60% of the maximum heart rate

SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

BACKGROUND: COVID-19 sequelae can affect about 15% of patients with cancer who survive the acute phase of SARS-CoV-2 infection and can substantially impair their survival and continuity of oncological care. We aimed to investigate whether previous immunisation affects long-term sequelae in the context of evolving variants of concern of SARS-CoV-2. METHODS: OnCovid is an active registry that includes patients aged 18 years or older from 37 institutions across Belgium, France, Germany, Italy, Spain, and the UK with a laboratory-confirmed diagnosis of COVID-19 and a history of solid or haematological malignancy, either active or in remission, followed up from COVID-19 diagnosis until death. We evaluated the prevalence of COVID-19 sequelae in patients who survived COVID-19 and underwent a formal clinical reassessment, categorising infection according to the date of diagnosis as the omicron (B.1.1.529) phase from Dec 15, 2021, to Jan 31, 2022; the alpha (B.1.1.7)-delta (B.1.617.2) phase from Dec 1, 2020, to Dec 14, 2021; and the pre-vaccination phase from Feb 27 to Nov 30, 2020. The prevalence of overall COVID-19 sequelae was compared according to SARS-CoV-2 immunisation status and in relation to post-COVID-19 survival and resumption of systemic anticancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974. FINDINGS: At the follow-up update on June 20, 2022, 1909 eligible patients, evaluated after a median of 39 days (IQR 24-68) from COVID-19 diagnosis, were included (964 [50·7%] of 1902 patients with sex data were female and 938 [49·3%] were male). Overall, 317 (16·6%; 95% CI 14·8-18·5) of 1909 patients had at least one sequela from COVID-19 at the first oncological reassessment. The prevalence of COVID-19 sequelae was highest in the pre-vaccination phase (191 [19·1%; 95% CI 16·4-22·0] of 1000 patients). The prevalence was similar in the alpha-delta phase (110 [16·8%; 13·8-20·3] of 653 patients, p=0·24), but significantly lower in the omicron phase (16 [6·2%; 3·5-10·2] of 256 patients, p<0·0001). In the alpha-delta phase, 84 (18·3%; 95% CI 14·6-22·7) of 458 unvaccinated patients and three (9·4%; 1·9-27·3) of 32 unvaccinated patients in the omicron phase had sequelae. Patients who received a booster and those who received two vaccine doses had a significantly lower prevalence of overall COVID-19 sequelae than unvaccinated or partially vaccinated patients (ten [7·4%; 95% CI 3·5-13·5] of 136 boosted patients, 18 [9·8%; 5·8-15·5] of 183 patients who had two vaccine doses vs 277 [18·5%; 16·5-20·9] of 1489 unvaccinated patients, p=0·0001), respiratory sequelae (six [4·4%; 1·6-9·6], 11 [6·0%; 3·0-10·7] vs 148 [9·9%; 8·4-11·6], p=0·030), and prolonged fatigue (three [2·2%; 0·1-6·4], ten [5·4%; 2·6-10·0] vs 115 [7·7%; 6·3-9·3], p=0·037). INTERPRETATION: Unvaccinated patients with cancer remain highly vulnerable to COVID-19 sequelae irrespective of viral strain. This study confirms the role of previous SARS-CoV-2 immunisation as an effective measure to protect patients from COVID-19 sequelae, disruption of therapy, and ensuing mortality. FUNDING: UK National Institute for Health and Care Research Imperial Biomedical Research Centre and the Cancer Treatment and Research Trust

Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

BACKGROUND: The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe. METHODS: In this retrospective analysis of the multicentre OnCovid Registry study, we recruited patients aged 18 years or older with laboratory-confirmed diagnosis of SARS-CoV-2, who had a history of solid or haematological malignancy that was either active or in remission. Patient were recruited from 37 oncology centres from UK, Italy, Spain, France, Belgium, and Germany. Participants were followed up from COVID-19 diagnosis until death or loss to follow-up, while being treated as per standard of care. For this analysis, we excluded data from centres that did not actively enter new data after March 1, 2021 (in France, Germany, and Belgium). We compared measures of COVID-19 morbidity, which were complications from COVID-19, hospitalisation due to COVID-19, and requirement of supplemental oxygen and COVID-19-specific therapies, and COVID-19 mortality across three time periods designated as the prevaccination (Feb 27 to Nov 30, 2020), alpha-delta (Dec 1, 2020, to Dec 14, 2021), and omicron (Dec 15, 2021, to Jan 31, 2022) phases. We assessed all-cause case-fatality rates at 14 days and 28 days after diagnosis of COVID-19 overall and in unvaccinated and fully vaccinated patients and in those who received a booster dose, after adjusting for country of origin, sex, age, comorbidities, tumour type, stage, and status, and receipt of systemic anti-cancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974, and is ongoing. FINDINGS: As of Feb 4, 2022 (database lock), the registry included 3820 patients who had been diagnosed with COVID-19 between Feb 27, 2020, and Jan 31, 2022. 3473 patients were eligible for inclusion (1640 [47·4%] were women and 1822 [52·6%] were men, with a median age of 68 years [IQR 57–77]). 2033 (58·5%) of 3473 were diagnosed during the prevaccination phase, 1075 (31·0%) during the alpha-delta phase, and 365 (10·5%) during the omicron phase. Among patients diagnosed during the omicron phase, 113 (33·3%) of 339 were fully vaccinated and 165 (48·7%) were boosted, whereas among those diagnosed during the alpha-delta phase, 152 (16·6%) of 915 were fully vaccinated and 21 (2·3%) were boosted. Compared with patients diagnosed during the prevaccination period, those who were diagnosed during the omicron phase had lower case-fatality rates at 14 days (adjusted odds ratio [OR] 0·32 [95% CI 0·19–0·61) and 28 days (0·34 [0·16–0·79]), complications due to COVID-19 (0·26 [0·17–0·46]), and hospitalisation due to COVID-19 (0·17 [0·09–0·32]), and had less requirements for COVID-19-specific therapy (0·22 [0·15–0·34]) and oxygen therapy (0·24 [0·14–0·43]) than did those diagnosed during the alpha-delta phase. Unvaccinated patients diagnosed during the omicron phase had similar crude case-fatality rates at 14 days (ten [25%] of 40 patients vs 114 [17%] of 656) and at 28 days (11 [27%] of 40 vs 184 [28%] of 656) and similar rates of hospitalisation due to COVID-19 (18 [43%] of 42 vs 266 [41%] of 652) and complications from COVID-19 (13 [31%] of 42 vs 237 [36%] of 659) as those diagnosed during the alpha-delta phase. INTERPRETATION: Despite time-dependent improvements in outcomes reported in the omicron phase compared with the earlier phases of the pandemic, patients with cancer remain highly susceptible to SARS-CoV-2 if they are not vaccinated against SARS-CoV-2. Our findings support universal vaccination of patients with cancer as a protective measure against morbidity and mortality from COVID-19. FUNDING: National Institute for Health and Care Research Imperial Biomedical Research Centre and the Cancer Treatment and Research Trust

Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry

Importance: Whether the severity and mortality of COVID-19 in patients with cancer have improved in terms of disease management and capacity is yet to be defined. Objective: To test whether severity and mortality from COVID-19 among patients with cancer have improved during the course of the pandemic. Design, Setting, and Participants: OnCovid is a European registry that collects data on consecutive patients with solid or hematologic cancer and COVID-19. This multicenter case series study included real-world data from 35 institutions across 6 countries (UK, Italy, Spain, France, Belgium, and Germany). This update included patients diagnosed between February 27, 2020, and February, 14, 2021. Inclusion criteria were confirmed diagnosis of SARS-CoV-2 infection and a history of solid or hematologic cancer. Exposures: SARS-CoV-2 infection. Main Outcomes and Measures: Deaths were differentiated at 14 days and 3 months as the 2 landmark end points. Patient characteristics and outcomes were compared by stratifying patients across 5 phases (February to March 2020, April to June 2020, July to September 2020, October to December 2020, and January to February 2021) and across 2 major outbreaks (February to June 2020 and July 2020 to February 2021). Results: At data cutoff, 2795 consecutive patients were included, with 2634 patients eligible for analysis (median [IQR] age, 68 [18-77] years; 52.8% men). Eligible patients demonstrated significant time-dependent improvement in 14-day case-fatality rate (CFR) with estimates of 29.8% (95% CI, 0.26-0.33) for February to March 2020; 20.3% (95% CI, 0.17-0.23) for April to June 2020; 12.5% (95% CI, 0.06-22.90) for July to September 2020; 17.2% (95% CI, 0.15-0.21) for October to December 2020; and 14.5% (95% CI, 0.09-0.21) for January to February 2021 (all P &lt;.001) across the predefined phases. Compared with the second major outbreak, patients diagnosed in the first outbreak were more likely to be 65 years or older (974 of 1626 [60.3%] vs 564 of 1008 [56.1%]; P =.03), have at least 2 comorbidities (793 of 1626 [48.8%] vs 427 of 1008 [42.4%]; P =.001), and have advanced tumors (708 of 1626 [46.4%] vs 536 of 1008 [56.1%]; P &lt;.001). Complications of COVID-19 were more likely to be seen (738 of 1626 [45.4%] vs 342 of 1008 [33.9%]; P &lt;.001) and require hospitalization (969 of 1626 [59.8%] vs 418 of 1008 [42.1%]; P &lt;.001) and anti-COVID-19 therapy (1004 of 1626 [61.7%] vs 501 of 1008 [49.7%]; P &lt;.001) during the first major outbreak. The 14-day CFRs for the first and second major outbreaks were 25.6% (95% CI, 0.23-0.28) vs 16.2% (95% CI, 0.13-0.19; P &lt;.001), respectively. After adjusting for country, sex, age, comorbidities, tumor stage and status, anti-COVID-19 and anticancer therapy, and COVID-19 complications, patients diagnosed in the first outbreak had an increased risk of death at 14 days (hazard ratio [HR], 1.85; 95% CI, 1.47-2.32) and 3 months (HR, 1.28; 95% CI, 1.08-1.51) compared with those diagnosed in the second outbreak. Conclusions and Relevance: The findings of this registry-based study suggest that mortality in patients with cancer diagnosed with COVID-19 has improved in Europe; this improvement may be associated with earlier diagnosis, improved management, and dynamic changes in community transmission over time.

Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective

Background: Specialist palliative care team (SPCT) involvement has been shown to improve symptom control and end-of-life care for patients with cancer, but little is known as to how these have been impacted by the COVID-19 pandemic. Here, we report SPCT involvement during the first wave of the pandemic and compare outcomes for patients with cancer who received and did not receive SPCT input from multiple European cancer centres. Methods: From the OnCovid repository (N = 1318), we analysed cancer patients aged ⩾18 diagnosed with COVID-19 between 26 February and 22 June 2020 who had complete specialist palliative care team data (SPCT+ referred; SPCT− not referred). Results: Of 555 eligible patients, 317 were male (57.1%), with a median age of 70 years (IQR 20). At COVID-19 diagnosis, 44.7% were on anti-cancer therapy and 53.3% had ⩾1 co-morbidity. Two hundred and six patients received SPCT input for symptom control (80.1%), psychological support (54.4%) and/or advance care planning (51%). SPCT+ patients had more ‘Do not attempt cardio-pulmonary resuscitation’ orders completed prior to (12.6% versus 3.7%) and during admission (50% versus 22.1%, p < 0.001), with more SPCT+ patients deemed suitable for treatment escalation (50% versus 22.1%, p < 0.001). SPCT involvement was associated with higher discharge rates from hospital for end-of-life care (9.7% versus 0%, p < 0.001). End-of-life anticipatory prescribing was higher in SPCT+ patients, with opioids (96.3% versus 47.1%) and benzodiazepines (82.9% versus 41.2%) being used frequently for symptom control. Conclusion: SPCT referral facilitated symptom control, emergency care and discharge planning, as well as high rates of referral for psychological support than previously reported. Our study highlighted the critical need of SPCTs for patients with cancer during the pandemic and should inform service planning for this population